Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SurModics Inc (SRDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
05/22/2025: SRDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 34.35% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 05/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 410.39M USD | Price to earnings Ratio - | 1Y Target Price 43 |
Price to earnings Ratio - | 1Y Target Price 43 | ||
Volume (30-day avg) 77821 | Beta 1.32 | 52 Weeks Range 26.00 - 42.44 | Updated Date 05/23/2025 |
52 Weeks Range 26.00 - 42.44 | Updated Date 05/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-04-30 | When Before Market | Estimate -0.11 | Actual -0.13 |
Profitability
Profit Margin -16.34% | Operating Margin (TTM) -5.38% |
Management Effectiveness
Return on Assets (TTM) -1.44% | Return on Equity (TTM) -16.96% |
Valuation
Trailing PE - | Forward PE 208.33 | Enterprise Value 418626596 | Price to Sales(TTM) 3.38 |
Enterprise Value 418626596 | Price to Sales(TTM) 3.38 | ||
Enterprise Value to Revenue 3.44 | Enterprise Value to EBITDA 179.57 | Shares Outstanding 14299300 | Shares Floating 12986879 |
Shares Outstanding 14299300 | Shares Floating 12986879 | ||
Percent Insiders 3.4 | Percent Institutions 84.55 |
Analyst Ratings
Rating 3.67 | Target Price 43 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
SurModics Inc
Company Overview
History and Background
SurModics, Inc. was founded in 1979. Initially focused on surface modification technologies, it has evolved into a provider of drug delivery technologies to the healthcare industry. Notable milestones include developing sustained release technologies and expanding into medical device coatings and in-vitro diagnostic components.
Core Business Areas
- Medical Device: Develops and manufactures surface modification technologies used to improve the performance of medical devices. These coatings enhance biocompatibility, lubricity, and drug delivery capabilities.
- IVD: Provides components and reagents for in-vitro diagnostic (IVD) assays, enabling improved assay performance and detection capabilities.
- Drug Delivery: Focuses on sustained release drug delivery technologies, designed to improve therapeutic outcomes and patient adherence.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other executive officers responsible for overseeing various functions. The organizational structure is hierarchical, with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Radiopaque Coating Technologies: Coatings that allow medical devices to be seen clearly on X-rays. Market share data not readily available. Competitors include AST Products, Inc., Biocoat, Inc.
- Seraguardu00ae: Provides protection against protein and cell adhesion. Market share data not readily available. Competitors include Hydromer, Harland Medical Systems, Inc.
- Drug Eluting Coating Technologies: Coatings that deliver drugs locally from medical devices. Market share data not readily available. Competitors include DSM, Covalon Technologies Ltd.
Market Dynamics
Industry Overview
The medical device and IVD industries are characterized by innovation, regulatory scrutiny, and intense competition. Key trends include the increasing demand for minimally invasive procedures and personalized medicine.
Positioning
SurModics holds a niche position as a provider of specialized surface modification and drug delivery technologies. Its competitive advantages stem from its expertise in materials science and its strong intellectual property portfolio.
Total Addressable Market (TAM)
The total addressable market is estimated to be in the billions of dollars annually. SurModics captures a small but important segment, offering specialized coatings and technologies.
Upturn SWOT Analysis
Strengths
- Strong intellectual property
- Expertise in surface modification technologies
- Established relationships with medical device manufacturers
- Diverse product portfolio
- High quality standards
Weaknesses
- Relatively small company size
- Dependence on medical device industry trends
- Limited marketing reach
- Concentrated customer base
- Sensitivity to regulatory changes
Opportunities
- Expanding into new therapeutic areas
- Developing novel drug delivery platforms
- Acquiring complementary technologies
- Capitalizing on the growing demand for personalized medicine
- Increasing global presence
Threats
- Intense competition from larger companies
- Patent expirations
- Regulatory hurdles
- Economic downturns
- Technological obsolescence
Competitors and Market Share
Key Competitors
- DHR
- BSX
- ABT
Competitive Landscape
SurModics holds a competitive position by providing specialized technologies, while facing significant competition from larger and more diversified medical device and diagnostic companies.
Major Acquisitions
Creagh Medical
- Year: 2023
- Acquisition Price (USD millions): 270
- Strategic Rationale: To add proprietary thrombectomy technologies to Surmodics' offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth cannot be provided without current company data.
Future Projections: Future Projections cannot be provided without current company data.
Recent Initiatives: Recent Initiatives cannot be provided without current company data.
Summary
SurModics is a niche player with specialized surface modification and drug delivery technologies. Their strengths lie in their intellectual property and established industry relationships. However, they are a relatively small company facing competition from larger players and need to focus on expanding into new markets. The acquisition of Creagh Medical is a positive step for them.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
COOK
Traeger Inc
COOK
Traeger Inc
DHR
Danaher Corporation
DHR
Danaher Corporation
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are estimates and may vary. Real-time financial data unavailable.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SurModics Inc
Exchange NASDAQ | Headquaters Eden Prairie, MN, United States | ||
IPO Launch date 1998-03-04 | CEO, President & Director Mr. Gary R. Maharaj | ||
Sector Healthcare | Industry Medical Devices | Full time employees 389 | Website https://www.surmodics.com |
Full time employees 389 | Website https://www.surmodics.com | ||
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
